secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007801
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms
--------------------------------------------------------------------------------

- Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.
- 1,318 patient start forms and 580 unique prescribers activated in the US through Dec 31, 2025.
- Prescription refills surpassed initial prescriptions as the primary revenue driver in Q4.
- Entered Latin America partnership with Multicare Pharma for Brazil, Argentina, Colombia, Mexico.
- Expect to file NDA for pediatric HAE patients (ages 2-11) in Q3 2026; US launch anticipated in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312526007801/0001193125-26-007801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312526007801/d11988d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer